search
Back to results

A Study of ZL-1211 in Patients With Advanced Solid Tumor

Primary Purpose

Advanced Solid Tumor

Status
Recruiting
Phase
Phase 1
Locations
International
Study Type
Interventional
Intervention
ZL-1211
Sponsored by
Zai Biopharmaceutical (Suzhou) Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Advanced Solid Tumor focused on measuring CLDN18.2, Solid tumor

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Patients are eligible to be included in the study only if all the following inclusion criteria apply:

  1. Adults≥ 18 years of age.
  2. Willing and able to provide signed and dated informed consent prior to any study related procedures and willing and able to comply with all study procedures.
  3. All patients from Phase I and Phase II are required to provide tumor tissue for CLDN18.2 IHC assessment, and only patients with CLDN18.2-positive tumors will be included in this study.
  4. Patients with histologically or cytologically confirmed metastatic or locally advanced solid tumors, refractory to standard treatment
  5. Evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
  6. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
  7. Adequate hepatic function

    1. Total bilirubin ≤ 1.5 × upper limit of normal (ULN).
    2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN; AST or ALT ≤ 5 × ULN if liver metastases are present.
  8. Adequate renal function, as defined by serum creatinine < 1.5 × ULN OR calculated creatinine CL > 40 mL/min, Cockroft-Gault Equation:
  9. Hematological function defined as:

    1. Absolute neutrophil count ≥ 1.5 × 109/L without growth factor support in the 2 weeks prior to screening.
    2. Platelet count ≥ 100 × 109/L without transfusion in the 2 weeks prior to screening.
    3. Hemoglobin ≥ 9 g/dL without transfusion in the 2 weeks prior to screening.
  10. Prothrombin time, international normalized ratio or/and activated partial thromboplastin time < 1.5 × ULN.
  11. Recovery, to Grade 0-1, from AEs related to prior anticancer therapy except alopecia, < Grade 2 sensory neuropathy, lymphopenia.

Exclusion Criteria:

  1. Patient with known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome related illness or known active or chronic hepatitis B virus infection or hepatitis C virus.
  2. Any uncontrolled active infection.
  3. Previous exposure to any CLDN18.2 antibody or CLDN18.2 chimeric antigen receptor T cell therapy.
  4. Newly diagnosed or symptomatic brain metastases anticonvulsants are allowed.
  5. Severe cardiovascular disease; New York Heart Association Class II-IV heart failure within 6 months of screening; uncontrolled arrhythmia within 6 months of screening.
  6. Anticancer therapy or radiation therapy within 5 half-lives or 4 weeks (whichever is shorter) prior to screening; palliative radiotherapy within 2 weeks prior to screening.
  7. Major surgery within 4 weeks prior to first dose; minor surgery within 2 weeks prior to first dose.
  8. Symptomatic intrinsic lung disease (chronic obstructive pulmonary disease, pulmonary fibrosis).
  9. Gastrointestinal abnormalities including:

    1. Documented unresolved gastric outlet obstruction or persistent vomiting defined as ≥ 3 episodes within 24 hours.
    2. Active peptic ulcer disease required treatment in the past 3 months.
    3. Gastrointestinal bleeding as evidenced by hematemesis, hematochezia, or melena in the past 3 months without evidence of resolution documented by endoscopy or colonoscopy.
    4. Documented active colitis within 4 weeks prior to study entry, including infectious colitis, radiation colitis and ischemic colitis.
    5. History of ulcerative colitis or Crohn's disease.
  10. Patient has received systemic immunosuppressive therapy, including systemic corticosteroids 2 weeks prior to first dose of study drug.

Sites / Locations

  • Zai Lab Site 2012Recruiting
  • Zai Lab Site 2016Recruiting
  • Zai Lab Site 2014Recruiting
  • Zai Site 2020
  • Zai Lab Site 2015Recruiting
  • Zai Lab Site 2011Recruiting
  • Zai Lab Site 2023
  • Zai Lab Site 2013Recruiting
  • Zai Lab Site 2022Recruiting
  • Zai Lab Site 1725
  • Zai Lab Site 1548
  • Zai Lab Site 1551Recruiting
  • Zai Lab Site 1549Recruiting
  • Zai Lab Site 1202
  • Zai Lab Site 1537
  • Zai Lab Site 1539Recruiting
  • Zai Lab Site 1542
  • Zai Lab Site 1712
  • Zai Lab Site 1529Recruiting
  • Zai Lab Site 1714

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

ZL-1211 monotherapy

Arm Description

Outcomes

Primary Outcome Measures

Phase I :MTD or MAD
To determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) (if no MTD is defined) of ZL-1211
Phase I and Phase II: safety and tolerability
Incidence of Treatment-Related Adverse Events as Assessed by CTCAE v5.0
Phase II: preliminary antitumor activity
Objective response rate defined as the proportion of patients with partial response (PR) proportion of patients with partial response (PR) or complete response (CR) based on Investigator assessment of tumor lesions per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

Secondary Outcome Measures

Phase I and Phase II: pharmacokinetics (PK):AUC
Area under the curve (AUC)
Phase I and Phase II: pharmacokinetics (PK):Cmax
Maximum serum concentration (Cmax)
Phase I and Phase II: pharmacokinetics (PK):Tmax
Time to reach Cmax (Tmax)
Phase I and Phase II: pharmacokinetics (PK):Ctrough
Ctrough
Phase I and Phase II: pharmacokinetics (PK):Vss
Volume of distribution at steady state (Vss)
Phase I and Phase II: pharmacokinetics (PK):CL
Clearance (CL)
Phase I and Phase II: pharmacokinetics (PK):t1/2
Half-life (t1/2)
Phase I and Phase II: immunogenicity
Incidence of anti-drug antibodies (ADAs)
Phase I and Phase II: immunogenicity
Quantity of anti-drug antibodies (ADAs)
Phase II: preliminary antitumor activity
Duration of response (DOR), defined as the time from the first date of objective response (CR or PR) to the first documented date of disease progression per RECIST v1.1 or the date of death due to any cause, whichever occurs first

Full Information

First Posted
September 12, 2021
Last Updated
November 23, 2022
Sponsor
Zai Biopharmaceutical (Suzhou) Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT05065710
Brief Title
A Study of ZL-1211 in Patients With Advanced Solid Tumor
Official Title
A Phase I/II, First-in-Human, Open-Label, Dose Escalation Study of ZL- 1211 in Patients With Unresectable or Metastatic Solid Tumor
Study Type
Interventional

2. Study Status

Record Verification Date
November 2022
Overall Recruitment Status
Recruiting
Study Start Date
January 19, 2022 (Actual)
Primary Completion Date
February 2024 (Anticipated)
Study Completion Date
October 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Zai Biopharmaceutical (Suzhou) Co., Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study is a Phase I/II, open-label, dose escalation, and cohort expansion study designed to characterize the safety, tolerability, pharmacokinetic (PK), pharmacodynamics (PD), immunogenicity, and preliminary antitumor activity of ZL-1211 administered by IV infusion on a every 2 weeks (Q2W) schedule.
Detailed Description
The study consists of two stages, Phase I -Dose Escalation Phase to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) (if no MTD is defined) of ZL-1211, and Phase II -Cohort Expansion Phase to further define the safety and initial antitumor activity of ZL-1211 with the dose established in the Dose Escalation Phase.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Advanced Solid Tumor
Keywords
CLDN18.2, Solid tumor

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Model Description
Phase I, the Dose Escalation Phase of the study will enroll patients with locally advanced or metastatic solid tumors of any histology with positive CLDN18.2. Phase II, the Cohort Expansion Phase of the study, will be conducted after determination of the dose level (RP2D) for cohort expansion based on the results of Phase I to explore the preliminary efficacy.
Masking
None (Open Label)
Allocation
N/A
Enrollment
162 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
ZL-1211 monotherapy
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
ZL-1211
Intervention Description
Phase 1 dose escalation part will enroll about 12-42 patients, Phase 2 dose expansion part will enroll about 15-40 patients in each cohort
Primary Outcome Measure Information:
Title
Phase I :MTD or MAD
Description
To determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) (if no MTD is defined) of ZL-1211
Time Frame
One month
Title
Phase I and Phase II: safety and tolerability
Description
Incidence of Treatment-Related Adverse Events as Assessed by CTCAE v5.0
Time Frame
Approximately 10 months
Title
Phase II: preliminary antitumor activity
Description
Objective response rate defined as the proportion of patients with partial response (PR) proportion of patients with partial response (PR) or complete response (CR) based on Investigator assessment of tumor lesions per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Time Frame
Approximately 10 months
Secondary Outcome Measure Information:
Title
Phase I and Phase II: pharmacokinetics (PK):AUC
Description
Area under the curve (AUC)
Time Frame
Approximately 10 months
Title
Phase I and Phase II: pharmacokinetics (PK):Cmax
Description
Maximum serum concentration (Cmax)
Time Frame
Approximately 10 months
Title
Phase I and Phase II: pharmacokinetics (PK):Tmax
Description
Time to reach Cmax (Tmax)
Time Frame
Approximately 10 months
Title
Phase I and Phase II: pharmacokinetics (PK):Ctrough
Description
Ctrough
Time Frame
Approximately 10 months
Title
Phase I and Phase II: pharmacokinetics (PK):Vss
Description
Volume of distribution at steady state (Vss)
Time Frame
Approximately 10 months
Title
Phase I and Phase II: pharmacokinetics (PK):CL
Description
Clearance (CL)
Time Frame
Approximately 10 months
Title
Phase I and Phase II: pharmacokinetics (PK):t1/2
Description
Half-life (t1/2)
Time Frame
Approximately 10 months
Title
Phase I and Phase II: immunogenicity
Description
Incidence of anti-drug antibodies (ADAs)
Time Frame
Approximately 10 months
Title
Phase I and Phase II: immunogenicity
Description
Quantity of anti-drug antibodies (ADAs)
Time Frame
Approximately 10 months
Title
Phase II: preliminary antitumor activity
Description
Duration of response (DOR), defined as the time from the first date of objective response (CR or PR) to the first documented date of disease progression per RECIST v1.1 or the date of death due to any cause, whichever occurs first
Time Frame
Approximately 10 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients are eligible to be included in the study only if all the following inclusion criteria apply: Adults≥ 18 years of age. Willing and able to provide signed and dated informed consent prior to any study related procedures and willing and able to comply with all study procedures. All patients from Phase I and Phase II are required to provide tumor tissue for CLDN18.2 IHC assessment, and only patients with CLDN18.2-positive tumors will be included in this study. Patients with histologically or cytologically confirmed metastatic or locally advanced solid tumors, refractory to standard treatment Evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. Adequate hepatic function Total bilirubin ≤ 1.5 × upper limit of normal (ULN). Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN; AST or ALT ≤ 5 × ULN if liver metastases are present. Adequate renal function, as defined by serum creatinine < 1.5 × ULN OR calculated creatinine CL > 40 mL/min, Cockroft-Gault Equation: Hematological function defined as: Absolute neutrophil count ≥ 1.5 × 109/L without growth factor support in the 2 weeks prior to screening. Platelet count ≥ 100 × 109/L without transfusion in the 2 weeks prior to screening. Hemoglobin ≥ 9 g/dL without transfusion in the 2 weeks prior to screening. Prothrombin time, international normalized ratio or/and activated partial thromboplastin time < 1.5 × ULN. Recovery, to Grade 0-1, from AEs related to prior anticancer therapy except alopecia, < Grade 2 sensory neuropathy, lymphopenia. Exclusion Criteria: Patient with known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome related illness or known active or chronic hepatitis B virus infection or hepatitis C virus. Any uncontrolled active infection. Previous exposure to any CLDN18.2 antibody or CLDN18.2 chimeric antigen receptor T cell therapy. Newly diagnosed or symptomatic brain metastases anticonvulsants are allowed. Severe cardiovascular disease; New York Heart Association Class II-IV heart failure within 6 months of screening; uncontrolled arrhythmia within 6 months of screening. Anticancer therapy or radiation therapy within 5 half-lives or 4 weeks (whichever is shorter) prior to screening; palliative radiotherapy within 2 weeks prior to screening. Major surgery within 4 weeks prior to first dose; minor surgery within 2 weeks prior to first dose. Symptomatic intrinsic lung disease (chronic obstructive pulmonary disease, pulmonary fibrosis). Gastrointestinal abnormalities including: Documented unresolved gastric outlet obstruction or persistent vomiting defined as ≥ 3 episodes within 24 hours. Active peptic ulcer disease required treatment in the past 3 months. Gastrointestinal bleeding as evidenced by hematemesis, hematochezia, or melena in the past 3 months without evidence of resolution documented by endoscopy or colonoscopy. Documented active colitis within 4 weeks prior to study entry, including infectious colitis, radiation colitis and ischemic colitis. History of ulcerative colitis or Crohn's disease. Patient has received systemic immunosuppressive therapy, including systemic corticosteroids 2 weeks prior to first dose of study drug.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
ZL-1211-001 Study Director
Phone
+862161632588
Email
Study-ZL-1211-001@zailaboratory.com
Facility Information:
Facility Name
Zai Lab Site 2012
City
Scottsdale
State/Province
Arizona
ZIP/Postal Code
85258
Country
United States
Individual Site Status
Recruiting
Facility Name
Zai Lab Site 2016
City
Lynwood
State/Province
California
ZIP/Postal Code
90262
Country
United States
Individual Site Status
Recruiting
Facility Name
Zai Lab Site 2014
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46250
Country
United States
Individual Site Status
Recruiting
Facility Name
Zai Site 2020
City
Hackensack
State/Province
New Jersey
ZIP/Postal Code
07601
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
Zai Lab Site 2015
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45219
Country
United States
Individual Site Status
Recruiting
Facility Name
Zai Lab Site 2011
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37203
Country
United States
Individual Site Status
Recruiting
Facility Name
Zai Lab Site 2023
City
Fairfax
State/Province
Virginia
ZIP/Postal Code
22031
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
Zai Lab Site 2013
City
Spokane
State/Province
Washington
ZIP/Postal Code
99208
Country
United States
Individual Site Status
Recruiting
Facility Name
Zai Lab Site 2022
City
Tacoma
State/Province
Washington
ZIP/Postal Code
98405
Country
United States
Individual Site Status
Recruiting
Facility Name
Zai Lab Site 1725
City
Hefei
State/Province
Anhui
ZIP/Postal Code
230031
Country
China
Individual Site Status
Not yet recruiting
Facility Name
Zai Lab Site 1548
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100032
Country
China
Individual Site Status
Not yet recruiting
Facility Name
Zai Lab Site 1551
City
Harbin
State/Province
Heilongjiang
ZIP/Postal Code
150000
Country
China
Individual Site Status
Recruiting
Facility Name
Zai Lab Site 1549
City
Zhengzhou
State/Province
Henan
ZIP/Postal Code
450003
Country
China
Individual Site Status
Recruiting
Facility Name
Zai Lab Site 1202
City
Zhengzhou
State/Province
Henan
ZIP/Postal Code
450052
Country
China
Individual Site Status
Not yet recruiting
Facility Name
Zai Lab Site 1537
City
Wuhan
State/Province
Hubei
ZIP/Postal Code
430022
Country
China
Individual Site Status
Not yet recruiting
Facility Name
Zai Lab Site 1539
City
Jinan
State/Province
Shandong
ZIP/Postal Code
250014
Country
China
Individual Site Status
Recruiting
Facility Name
Zai Lab Site 1542
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200092
Country
China
Individual Site Status
Not yet recruiting
Facility Name
Zai Lab Site 1712
City
Chengdu
State/Province
Sichuan
ZIP/Postal Code
610044
Country
China
Individual Site Status
Not yet recruiting
Facility Name
Zai Lab Site 1529
City
Hangzhou
State/Province
Zhejiang
ZIP/Postal Code
310003
Country
China
Individual Site Status
Recruiting
Facility Name
Zai Lab Site 1714
City
Hangzhou
State/Province
Zhejiang
ZIP/Postal Code
310014
Country
China
Individual Site Status
Not yet recruiting

12. IPD Sharing Statement

Learn more about this trial

A Study of ZL-1211 in Patients With Advanced Solid Tumor

We'll reach out to this number within 24 hrs